| Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics Y Wang, S Zhang, F Li, Y Zhou, Y Zhang, Z Wang, R Zhang, J Zhu, Y Ren, ... Nucleic acids research 48 (D1), D1031-D1041, 2020 | 816 | 2020 |
| Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics YH Li, CY Yu, XX Li, P Zhang, J Tang, Q Yang, T Fu, X Zhang, X Cui, G Tu, ... Nucleic acids research 46 (D1), D1121-D1127, 2018 | 523 | 2018 |
| NOREVA: normalization and evaluation of MS-based metabolomics data B Li, J Tang, Q Yang, S Li, X Cui, Y Li, Y Chen, W Xue, X Li, F Zhu Nucleic acids research 45 (W1), W162-W170, 2017 | 348 | 2017 |
| Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information H Yang, C Qin, YH Li, L Tao, J Zhou, CY Yu, F Xu, Z Chen, F Zhu, ... Nucleic acids research 44 (D1), D1069-D1074, 2016 | 289 | 2016 |
| Consistent gene signature of schizophrenia identified by a novel feature selection strategy from comprehensive sets of transcriptomic data Q Yang, B Li, J Tang, X Cui, Y Wang, X Li, J Hu, Y Chen, W Xue, Y Lou, ... Briefings in Bioinformatics 21 (3), 1058-1068, 2020 | 195 | 2020 |
| ANPELA: analysis and performance assessment of the label-free quantification workflow for metaproteomic studies J Tang, J Fu, Y Wang, B Li, Y Li, Q Yang, X Cui, J Hong, X Li, Y Chen, ... Briefings in bioinformatics 21 (2), 621-636, 2020 | 162 | 2020 |
| Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs YH Li, XX Li, JJ Hong, YX Wang, JB Fu, H Yang, CY Yu, FC Li, J Hu, ... Briefings in Bioinformatics 21 (2), 649-662, 2020 | 157 | 2020 |
| Therapeutic target database update 2014: a resource for targeted therapeutics C Qin, C Zhang, F Zhu, F Xu, SY Chen, P Zhang, YH Li, SY Yang, YQ Wei, ... Nucleic acids research 42 (D1), D1118-D1123, 2014 | 154 | 2014 |
| SVM-Prot 2016: a web-server for machine learning prediction of protein functional families from sequence irrespective of similarity YH Li, JY Xu, L Tao, XF Li, S Li, X Zeng, SY Chen, P Zhang, C Qin, ... PloS one 11 (8), e0155290, 2016 | 135 | 2016 |
| Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder W Xue, P Wang, G Tu, F Yang, G Zheng, X Li, X Li, Y Chen, X Yao, F Zhu Physical Chemistry Chemical Physics 20 (9), 6606-6616, 2018 | 130 | 2018 |
| Exploring the binding mechanism of metabotropic glutamate receptor 5 negative allosteric modulators in clinical trials by molecular dynamics simulations T Fu, G Zheng, G Tu, F Yang, Y Chen, X Yao, X Li, W Xue, F Zhu ACS chemical neuroscience 9 (6), 1492-1502, 2018 | 108 | 2018 |
| Clinical success of drug targets prospectively predicted by in silico study F Zhu, XX Li, SY Yang, YZ Chen Trends in Pharmacological Sciences 39 (3), 229-231, 2018 | 105 | 2018 |
| MMEASE: online meta-analysis of metabolomic data by enhanced metabolite annotation, marker selection and enrichment analysis Q Yang, B Li, S Chen, J Tang, Y Li, Y Li, S Zhang, C Shi, Y Zhang, M Mou, ... Journal of Proteomics 232, 104023, 2021 | 89 | 2021 |
| Discovery of the consistently well-performed analysis chain for SWATH-MS based pharmacoproteomic quantification J Fu, J Tang, Y Wang, X Cui, Q Yang, J Hong, X Li, S Li, Y Chen, W Xue, ... Frontiers in Pharmacology 9, 681, 2018 | 70 | 2018 |
| The human kinome targeted by FDA approved multi-target drugs and combination products: A comparative study from the drug-target interaction network perspective YH Li, PP Wang, XX Li, CY Yu, H Yang, J Zhou, WW Xue, J Tan, F Zhu PloS one 11 (11), e0165737, 2016 | 69 | 2016 |
| Exploring the inhibitory mechanism of approved selective norepinephrine reuptake inhibitors and reboxetine enantiomers by molecular dynamics study G Zheng, W Xue, P Wang, F Yang, B Li, X Li, Y Li, X Yao, F Zhu Scientific reports 6 (1), 26883, 2016 | 51 | 2016 |
| Comparison of FDA approved kinase targets to clinical trial ones: insights from their system profiles and drug‐target interaction networks J Xu, P Wang, H Yang, J Zhou, Y Li, X Li, W Xue, C Yu, Y Tian, F Zhu BioMed Research International 2016 (1), 2509385, 2016 | 46 | 2016 |
| Prediction of the binding mode and resistance profile for a dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase-associated ribonuclease H F Yang, G Zheng, T Fu, X Li, G Tu, YH Li, X Yao, W Xue, F Zhu Physical Chemistry Chemical Physics 20 (37), 23873-23884, 2018 | 31 | 2018 |
| What makes species productive of anti-cancer drugs? Clues from drugs’ species origin, druglikeness, target and pathway X Li, X Li, Y Li, C Yu, W Xue, J Hu, B Li, P Wang, F Zhu Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2019 | 20 | 2019 |
